BioElectronics Corporation
(A Development Stage Company)

UNAUDITED FINANCIAL STATEMENTS

FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2015 AND 2014

Trading Symbol: BIEL
CUSIP Number: 09062H108

These financial statements have not been subjected to an audit, review or compilation engagement, and no assurance is provided on them.

Table of Contents

PAGE

BioElectronics Corporation (A Development Stage Company)
Balance Sheets
(Unaudited)

	September 30, 2015	December 31, 2014
Assets		
Current assets:		
Cash and cash equivalents	$ 23,521	$ 45,342
Trade and other receivables, net	251,499	234,523
Inventory	349,912	393,330
Total current assets	624,932	673,195
Property and equipment	181,061	181,061
Less: Accumulated depreciation	(171,664)	(161,639)
Property and equipment, net	9,397	19,422
Total assets	$ 634,329	$ 692,617
Liabilities and stockholders' deficiency		
Current liabilities:		
Accounts payable and accrued expenses	$ 732,119	$ 482,361
Deferred revenue	28,760	18,014
Related party notes payable, current portion	6,102,152	2,058,447
Notes Payable	539,545	564,138
Total current liabilities	7,402,576	3,122,960
Long-term liabilities:		
Related party notes payable, net of discount	2,289,758	5,718,002
Total liabilities	9,692,334	8,840,962
Commitments and contingencies		
Stockholders' deficiency:		
Common stock, par value $0.001 per share, 10,000,000,000 and 7,000,000,000 shares authorized at September 30, 2015 and December 31, 2014, respectively, and 9,274,346,731 and 6,409,215,686 shares issued and outstanding at September 30, 2015 and December 31, 2014, respectively	9,274,347	6,409,216
Additional paid-in capital	8,859,975	10,519,966
Deficit accumulated during the development stage	(27,192,327)	(25,077,527)
Total stockholders' deficiency	(9,058,005)	(8,148,345)
Total liabilities and stockholders' deficiency	$ 634,329	$ 692,617

BioElectronics Corporation (A Development Stage Company)
Condensed Statements of Operations
For the Three and Nine Months Ended September 30, 2015 and 2014
(Unaudited)

	For the Three Months Ended		For the Nine Months Ended	
	September 30, 2015	September 30, 2014	September 30, 2015	September 30, 2014
Sales	$ 499,869	$ 231,174	$ 1,678,665	$ 677,454
Cost of Goods Sold	180,065	181,554	846,467	475,489
Gross profit	319,804	49,620	832,198	201,965
General and Administrative Expenses:				
Bad Debt Expense	46,170	(11,897)	45,292	(22,955)
Depreciation and Amortization	2,794	4,655	10,025	12,305
Investor Relations Expenses	83,580	69,927	203,206	160,087
Legal and Accounting Expenses	53,685	22,124	187,052	89,912
Sales Support Expenses	243,708	180,969	743,373	436,097
Research and Development	178,992	50,843	384,610	245,382
Other General and Administrative Expenses	283,914	300,341	904,834	974,371
Total General and Administrative Expenses	892,843	616,962	2,478,392	1,895,199
Loss from Operations	(573,039)	(567,342)	(1,646,194)	(1,693,234)
Interest Expense and Other, Net:				
Other Income(Expense)	-	(549)	-	(60)
Interest Expense	(154,310)	(155,482)	(468,606)	(409,653)
Total Interest Expense and Other, Net	(154,310)	(156,031)	(468,606)	(409,713)
Loss Before Income Taxes	(727,349)	(723,373)	(2,114,800)	(2,102,947)
Provision for Income Tax Expense	-	-	-	-
Net loss	$ (727,349)	$ (723,373)	$ (2,114,800)	$ (2,102,947)
Net loss Per Share - Basic and Diluted	$ (0.0001)	$ (0.0001)	$ (0.0003)	$ (0.0004)
Weighted Average Number of Shares Outstanding - Basic and Diluted	8,636,687,667	6,049,205,179	7,841,781,209	5,038,863,913

BioElectronics Corporation (A Development Stage Company)
Statements of Cash Flows
For the Nine Months Ended September 30, 2015 and 2014
(Unaudited)

	September 30, 2015	September 30, 2014
Cash Flows From Operating Activities:		
Net Loss	$ (2,114,800)	$ (2,102,947)
Adjustment to Reconcile Net Loss to		
Net Cash Used in Operating Activities:		
Depreciation and amortization	10,025	12,305
Provision for bad debts	45,292	-
Non-cash expenses	140,000	72,397
Non-cash interest related to related party notes payable	469,692	394,125
Changes in Assets and Liabilities		
(Increase) Decrease in:		
Trade and other receivables	(62,268)	(48,035)
Inventory	43,418	142,470
Increase (Decrease) in:		
Accounts payable and accrued expenses	268,749	(263,546)
Deferred revenue	10,746	(76,932)
Net Cash Used In Operating Activities	(1,189,146)	(1,870,163)
Cash Flows From Investing Activities		
Acquisition of property and equipment	-	(11,050)
Net Cash Used In Investing Activities	-	(11,050)
Cash Flows From Financing Activities		
Payments on note payable	(30,834)	-
Payments on related party notes payable	(70,826)	-
Proceeds from related party notes payable	1,223,985	1,855,499
Proceeds from notes payable	45,000	-
Net Cash Provided By Financing Activities	1,167,325	1,855,499
Net Increase (Decrease) In Cash	(21,821)	(25,714)
Cash- Beginning of Period	45,342	28,603
Cash- End of Period	$ 23,521	$ 2,889
Supplemental Disclosures Of Cash Flow Information:		
Cash paid during the periods for interest	$ 15,931	$ 15,528
Supplemental Schedule of Non-Cash Investing and Financing Activities:		
Conversion of debt and accrued interest into common stock	$ 1,114,390	$ 1,927,515
Issuance of convertible debt with beneficial conversion interest	$ 53,413	$ -
Conversion of warrants into common stock	$ -	$ -
Equipment purchases financed through capital leases and notes payable	$ -	$ -

NOTE 1- NATURE OF BUSINESS

BioElectronics Corporation was incorporated in April 2000 and began employee-based operations in 2003. The Company is the developer, marketer and manufacturer of patented, inexpensive, drug-free, topical pain medical devices. The devices consist of a microchip, battery and antenna that deliver the therapy. The devices provide 30 days of continuous pain relief for the following applications: (1) Back; (2) Neck; (3) Knee; (4) Wrist and Elbow; (5) Smart Insole™ for Heel Pain; (6) Allay® Menstrual Cycle Pain Therapy and RecoveryRx® for post-operative and chronic wound care.

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The Company has prepared the financial statements in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP).

Development Stage Company

As defined by Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 915, "Development Stage Entities", the Company is devoting substantially all of its present efforts to developing its business. The Company has not yet commenced one of its planned principal activities, the sale of products in the U.S. retail market. All losses accumulated since inception have been considered as part of the Company's development stage activities. Costs of start-up activities, including organizational costs, are expensed as incurred.

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosures of contingent assets and liabilities as of the date of the financial statements, and the reported amounts of revenue and expenses during the reporting period. The more significant estimates include inventory obsolescence reserve, useful lives for depreciation and amortization, salvage values of depreciable equipment, valuation of warrants, nonvested restricted shares, stock options, and allowance for doubtful accounts receivable. Actual results could differ from these estimates.

Cash and Cash Equivalents

The Company considers all highly liquid instruments purchased with an original maturity of three months or less as cash equivalents.

Trade Receivables

The Company maintains reserves on customer accounts where estimated losses may result from the inability of its customers to make required payments. These reserves are determined based on a number of factors, including the current financial condition of specific customers, the age of trade and other receivable balances and historical loss rate. The allowance for doubtful accounts was $73,622 and $17,453 at September 30, 2015 and December 31, 2014, respectively. Bad debt expense for the nine months ended September 30, 2015 and September 30, 2014 was $45,292 and $(22,955), respectively.

Revenue Recognition

The Company sells its products to wholesale distributors and directly to hospitals and clinics. Revenue is recognized when evidence of an arrangement exists, pricing is fixed and determinable, collection is reasonably assured, and shipment has occurred. Payment is due on a net basis in 60 days. If the customer is deemed not credit worthy, payment in advance is required. Payments received in advance of when revenue is recognized are recorded as deferred revenue on the balance sheets and recognized as revenue when the goods are shipped and all other general revenue recognition criteria have been met. No allowance for sales returns is required for the nine months ended September 30, 2015 and September 30, 2014. Defective units are replaced at the request of the customer.

Advertising Costs

The Company expenses the costs associated with advertising as incurred. Advertising expenses for the nine months ended September 30, 2015 and September 30, 2014 were $611,071 and $214,044, respectively, and included in sales support expenses.

Income Taxes

The Company accounts for income taxes under the provisions of SFAS No, 109, "Accounting for Income Taxes." SFAS 109 requires recognition of deferred tax assets and liabilities for the expected future tax consequences attributable to the differences between the financial statement carrying amounts of existing assets and liabilities, and their respective tax bases and operating loss carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to be applied to taxable income in the years in which those temporary differences are expected to be recovered or settled. A valuation allowance is provided to offset any deferred tax assets that may not be realized.

Research and Development

Research and development costs include the costs of clinical studies, which are expensed as incurred, along with staff dedicated to research and development. The Company incurred $384,610 and $245,382 for the nine months ended September 30, 2015 and 2014, respectively.

Stock Incentive Plans and Other Share-Based Compensation

The Company recognizes the cost of employee services received in exchange for awards of equity instruments based upon the grant date fair value of those awards.

Net Loss per Share

The Company calculates basic and diluted net loss per share in accordance with ASC Topic 260, "Earnings per Share", which requires the presentation of basic and diluted net loss per share on the face of the Statement of Operations. Basic and diluted net loss per share is computed by dividing net loss by the weighted average number of outstanding shares of common stock. Convertible debt instruments, warrants, and options to purchase common stock are included as common stock equivalents only when dilutive. For the nine months ended September 30, 2015 and 2014 the Company reported net losses, and as a result there is no difference between basic and diluted shares for each of the years presented.

Issuance Of Stock For Non-Cash Consideration

All issuances of the Company's stock for non-cash consideration have been assigned a per share amount determined with reference to the value of consideration received, which has been determined to be a more readily determinable fair value than the fair value of the common stock. The majority of the non-cash consideration pertains to services rendered by consultants and vendors. The fair value of the services received was used to record the related expense in the statement of operations and fair value was attributed to the shares issued.

The Company's accounting policy for equity instruments issued to consultants and vendors in exchange for goods and services follows the provisions of ASC Topic 505-50, "Equity-Based Payments to Non-Employees." The measurement date for the fair value of the equity instruments issued is determined at the earlier of (i) the date at which a commitment for performance by the consultant or vendor is reached or (ii) the date at which the consultant or vendor's performance is complete.

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

Stockholders' Equity Transactions

On June 18, 2009, the Company authorized to increase the number of common shares from 750,000,000 to 1,000,000,000, with further increases to 1,500,000,000 in 2010, to 2,000,000,000 in 2011, to 3,000,000,000 in 2012, to 4,000,000 in 2013, to 7,000,000,000 in 2014, and to 10,000,000,000 in 2015. These increases are a result of the continued requirement to cover the potential issuance of common stock resulting from the conversion of debt to equity. The holders of the remaining shares to be issued upon conversion or exercise of equity instruments are likely to promptly sell those shares into the public market. The resale of these shares could have a negative impact on the stock price, and these conversions would have a dilutive impact on our shareholders. As a result, our net income per share could decrease for future periods, and the market price of our common stock could decline.

NOTE 3 – GOING CONCERN

The Company's financial statements have been prepared on a going concern basis which contemplates the realization of assets and the liquidation of liabilities in the ordinary course of business. The Company has incurred substantial losses from operations. The Company sustained a net loss of $2,114,800 for the nine months ended September 30, 2015, and a total net loss since inception of $27,192,327. The Company is currently seeking financing to provide the needed funds for operations. However, the Company can provide no assurance that it will be able to obtain the financing it needs to continue its efforts for market acceptance, U.S. FDA approval and to maintain operations and alleviate doubt about its ability to continue as a going concern.

NOTE 4 - INVENTORY

The components of inventory consisted of the following as of:

	September 30, 2015	December 31, 2014
Raw materials	$ 197,164	$ 258,781
Prepaid inventory	48,945	51,060
Finished goods	103,803	83,489
	$ 349,912	$ 393,330

NOTE 5 – PROPERTY AND EQUIPMENT, NET

Property and equipment, net consists of the following as of:

	September 30, 2015	December 31, 2014
Machinery & Equipment	$ 174,179	$ 174,179
Leasehold improvements	6,882	6,882
	181,061	181,061
Less: accumulated depreciation	171,664	161,639
Total property and equipment, net	$ 9,397	$ 19,422

For the nine months ended September 30, 2015 and 2014, depreciation expense on property and equipment amounted to $10,025 and $12,305, respectively.

NOTE 6 – LINE OF CREDIT

In May 2013, the Company finalized a line of credit agreement with the Export-Import Bank of the United States. The line of credit was originally for $500,000 at a fixed interest rate of 5.07%, and has now been modified and extended, with the line of credit set at $485,000 and the September 30, 2015 balance including accured interest at $494,293. For the nine months ended September 30, 2015 and 2014, total interest expense on the line of credit amounted to $18,739 and $15,528, respectively.

NOTE 7 – RELATED PARTY NOTES PAYABLE

IBEX Convertible Notes Payable

IBEX, LLC is a limited liability company, whose President is the daughter of the President of the Company. Beginning on August 1, 2009, the Company started entering into convertible promissory note agreements with IBEX with simple interest at 8% per year. All accrued interest and principal on the various notes payable are due on or before the end of the month two years from the date of issuance, whether by the payment of cash or by conversion into shares of the Company's common stock, unless otherwise extended with new terms. According to the original Security Agreement dated August 1, 2009, the Company grants IBEX a security interest in, all of the right, title, and interest of the Company, in and to all of the Company's personal property and intellectual property, and all proceeds or replacements as collateral for the convertible promissory note agreements.

The conversion price on the IBEX notes have generally been 50% or less of the pink sheet closing price of the common stock on the date the notes were issued, to reflect the restricted nature of the stock for which the notes could be converted, and the Board of Directors' belief that the closing proce is not necessarily reflective of the fiar market value of the common stock, due to the price volatility, and the lack of an active trading market to establish the value of the shares. The Board of Directors is active in negotiating conversion prices for each issuance, and takes into consideration all information in establishing the issuance date conversion price.

On August 31, 2011, the date of maturity for notes payable of $519,920, the Company did not have sufficient cash on hand to pay the amount due, so the Company and issuer entered into an agreement to change the conversion price of the note to the market price of the restricted shares. The Conversion Price was thus changed from the original amount of $.019 per share to $.015 per share, the share market price on that date. The maturity date on the note agreement was extended to September 30, 2015, with a new conversion price of $.0008 per share.

Starting in 2012 and continuing through September 2015, the Company extended the maturity dates by one year and two years on several separate notes through multiple agreements with IBEX, as a result of insufficient cash to make payments on amounts owed. In exchange for the extensions, the conversion prices were changed to 50% of the existing market price of the Common Stock on the date of the maturity. While IBEX sold notes valued at $1,056,640 during the nine months ended September 2015 to third parties, with most of those third parties converting those notes into common shares, the Company continued to borrow from IBEX, with new borrowings totaling $898,860 during the nine months ended September 30, 2015. Due to the continued borrowing from IBEX, the corresponding shares to be issued on the conversion of these IBEX notes has increased from 11,716,139,856 at December 31, 2014 to 12,161,135,052 at September 30, 2015.

During the nine months ended September 30, 2015 and 2014, the Company borrowed $898,860 and $1,703,305, respectively, through additional promissory notes with IBEX. The balance on these notes as of September 30, 2015 and December 31, 2014 were $5,364,682 and $5,273,536, respectively.

Total interest expense on the IBEX convertible promissory notes payable for the nine months ended September 30, 2015 and 2014 was $319,572 and $297,648, respectively.

NOTE 7 – RELATED PARTY NOTES PAYABLE (Continued)

Other Related Party Convertible Notes Payable

The Company has entered into convertible promissory note agreements with various other related parties of the Company. Other related parties consist of Robert Whelan and Janel Zaluski, the son and daughter of the President, Mary Whelan, the sister of the President, St. John's LLC, which is owned by family members of the President, and Richard Staelin, who is Chairman of the Board of Directors.

Each of the other related party promissory notes bears simple interest at 8% per annum, and all accrued interest and principal is due on the maturity date. At the option of the holder, the promissory notes are convertible into common shares of the Company's stock at a conversion rate equal to the quotient of (i) a sum equal to the entire outstanding principal and interest, divided by (ii) the conversion price.

Similar to the IBEX promissory notes, the conversion prices per the terms of the note agreements are based on the fair value of the OTC closing price of the Company's stock as of the date of issuance, discounted based on the factors previously discussed in the disclosures related to the IBEX notes. There were no related party loan conversions during the nine months ended September 30, 2015 and 2014, respectively.

During the nine months ended September 30, 2015 and 2014, the Company borrowed $374,375 and $92,675, respectively, through additional promissory notes with other related parties. Total interest expense for the nine months ended September 30, 2015 and 2014, was $150,120 and $131,569, respectively.

The balances on these other related party loans amounted to $3,027,408 at September 30, 2015 and $2,502,913 at December 31, 2014. Due to the new loans and the drop in stock prices, the corresponding shares to be issued on the conversion of these other related party loans has increased from 5,393,518,265 at December 31, 2014 to 7,088,010,308 at September 30, 2015.

NOTE 8 – LOSS PER SHARE

The following table sets forth the computation of basic and diluted share data:

	Six Months Ended June 30,	
Common Stock:	2015	2014
Weighted Average Number of Shares Outstanding - Basic	7,204,122,144	4,870,234,359
Effect of Dilutive Securities:		
Options and Warrants	-	-
Weighted Average Number of Shares Outstanding - Diluted	7,204,122,144	4,870,234,359
Options and Warrants Not Included Above (Antidilutive)		
Nonvested Restricted Share Awards	40,000,000	10,233,333
Options to Purchase Common Stock	793,700,000	333,700,000
	833,700,000	343,933,333

NOTE 9 – SHARE BASED COMPENSATION

On November 30, 2004, as amended March 22, 2005, the Company adopted the BioElectronics Equity Incentive Plan ("the Plan"), for the purpose of providing incentives for officers, directors, consultants and key employees to promote the success of the Company, and to enhance the Company's ability to attract and retain the services of such persons.

The Plan initially reserved 10 million shares of common stock for issuance, which was amended to 100 million shares on March 1, 2010. In 2012 the plan was amended to 200 million shares available for future grant, further amended to 300 million shares in 2013, and 500 million shares in 2014. The issuance can be in the forms of options or shares. The options may be incentive, nonqualified or stock appreciation rights. The shares may be issued for performance.

Stock Option Awards

On September 1, 2011, the Company granted stock options to a third party vendor with a grant date fair value of $0.005 per share. The exercise price is $0.005 per share with a term of ten years and a three year vesting period, with one-third of the options vesting on each anniversary date after the initial date of grant. The option awards were granted with an exercise price equal to the Company's closing bid price on the Over-the-Counter Pink Sheets on the date of grant, discounted fifty percent for lack of marketability, which was deemed to be fair value.

In January 2012, the Company granted 55.0 million stock options with an exercise price of $0.0029 per share, with immediate vesting. The option awards were granted with an exercise price slightly less than the Company's closing bid price on the Over-the-Counter Pink Sheets on the date of grant.

On August 29, 2012, the Company granted stock options to employees of the Company, the Chairman of the Board and a shareholder of the Company with a grant date fair value of $0.0029 per share. The exercise price is $0.0022 per share with a term of five years and a three year vesting period, with one-third of the options vesting on each anniversary date after the initial date of grant. The option awards were granted with an exercise price equal to the Company's closing bid price on the Over-the-Counter Pink Sheets on the date of grant, discounted fifty percent for lack of marketability, which was deemed to be fair value.

In April 2013, the Company granted 85.0 million stock options to employees of the Company, with a grant date exercise price of $0.0015 per share. The exercise price is at a discount of around 50% relative to the market price of $0.0031 per share.

In December 2013, the Company granted 90.0 million stock options to employees of the Company, with a grant date exercise price of $0.0007 per share. The exercise price is at a discount of around 13% relative to the market price of $0.0008 per share.

In March 2014, the Company granted 210.0 million stock options to an Executive Vice President, with three tranches of 70.0 million each with prices ranging from $.0014 to $.015 per share, with each tranche exercisable on the first, second and third anniversaries of the grant, and each vesting over a three-year period.

In March 2014, the Company granted 250.0 million stock options to employees of the Company, with a grant date exercise price of $0.0015 per share (50% of market price).

No stock options were awarded in the first nine months of 2015.

Nonvested Restricted Share Awards

In prior years, the Company also issued nonvested restricted share awards to directors, consultants and employees. The nonvested restricted share awards vest over a three year period based on the requisite service period. Compensation expense related to the fair value of these awards is recognized straight-line over the requisite service period based on those restricted stock grants that ultimately vest. The fair value of grants is measured by the market price of the Company’s common stock on the date of grant discounted by 50 percent based on the restricted nature of the stock, the volatility in the market and other variables taken into account by the Board of Directors in determining the fair value of the restricted share awards.

Restricted stock awards generally vest ratably over the service period beginning with the first anniversary of the grant date. After shares are vested, they will be issued upon the request of the grantee.

NOTE 9 – SHARE BASED COMPENSATION (Continued)

In March 2014, the Company issued 40.0 million shares of restricted stock to an Executive Vice President, vesting in equal thirds on the first three anniversaries of the grant.

NOTE 10 – INCOME TAXES

The Company has not provided for income tax expense for the nine months ended Sepember 30, 2015 because of a significant net operating loss carry-forward of approximately $27 million. The net operating losses expire in various years through 2034.

In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which these temporary differences become deductible.

Based on available evidence, Company's management believes that it is more likely than not that the Company will not be able to realize the benefit of its net deferred tax assets as of September 30, 2015 and 2014, and that a full valuation reserve is needed to reduce the net deferred tax asset value to $0 for each year.

NOTE 11 – FAIR VALUE MEASUREMENTS

The Company's financial instruments consist primarily of cash, trade and other receivables, accounts payable and accrued expenses, notes payable and related party notes payable. The carrying amounts of such financial instruments approximate their respective estimated fair value due to the short-term maturities and approximate market interest rates of these instruments. The estimated fair value is not necessarily indicative of the amounts the Company would realize in a current market exchange or from future earnings or cash flows. The Company adopted ASC Topic 820-10, "Fair Value Measurements and Disclosures", which defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements. The standard provides a consistent definition of fair value which focuses on an exit price that would be received upon sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.

The standard also prioritizes, within the measurement of fair value, the use of market-based information over entity specific information and establishes a three-level hierarchy for fair value measurements based on the nature of inputs used in the valuation of an asset or liability as of the measurement date.

The three-level hierarchy for fair value measurements is defined as follows:

- Level 1 – inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets

- Level 2 – inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability other than quoted prices, either directly or indirectly including inputs in markets that are not considered to be active

- Level 3 – inputs to the valuation methodology are unobservable and significant to the fair value measurement

An investment's categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.

NOTE 12 – COMMITMENTS AND CONTINGENCIES

In the ordinary course of conducting its business, the Company may become involved in various legal actions and other claims, some of which are currently pending. Litigation is subject to many uncertainties and management may be unable to accurately predict the outcome of individual litigated matters. Some of these matters may possibly be decided unfavorably towards the Company.

The Company is involved, on a continuing basis, in monitoring our compliance with environmental laws and in making capital and operating improvements necessary to comply with existing and anticipated environmental requirements. While it is impossible to predict with certainty, management currently does not foresee such expenses in the future as having a material effect on the business, results of operations, or financial condition of the Company.

NOTE 13 – RELATED PARTY TRANSACTIONS

In addition to the related party transactions disclosed in Note 7, BioElectronics signed a distribution agreement on February 9, 2009 with eMarkets Group, LLC (eMarkets) a company owned and controlled by a member of the Board of Directors and sister of the company's President. The agreement provides for eMarkets to be the exclusive distributor of the veterinary products of the Company to customers in certain countries outside of the United States. The distribution agreement lists the prices to be paid for the company's products by eMarkets and provides for the company to provide training and customer support at its own cost to support the distributor’s sales function.

Revenue from eMarkets for the nine months ended September 30, 2015 and 2014 amounted to $10,543 and $10,337, respectively. The balance in accounts receivable from eMarkets as of September, 2015 and December 31, 2014 was $0 and $617, respectively.

NOTE 14 – CONCENTRATIONS

As of September 30, 2015, 92% of gross trade receivables was from two customers, and for the nine months ended September 30, 2015, 85% of sales revenue was from the top five customers. Approximately 60% of all sales for the nine months ended September 30, 2015 were in the United Kingdom.

As of September 30, 2015, 59% of accounts payable was with six vendors. For the nine months ended September 30, 2015, all inventory purchases were from three vendors.